Continuous-flow fluoro-immunosensor for paclitaxel measurement

Sheikh, Sohail Hamid; Mulchandani, Ashok

doi:10.1016/s0956-5663(01)00193-2

Cited by 23 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although this dose was above therapeutic concentrations, the actual drug concentrations determined to cause 50% growth inhibition (Additional File 1) ranged from 0.104 nM to 7.96 μM. The minimum is below the therapeutic concentration range's minimum of 100 nM, while our maximum is slightly below the maximum therapeutic concentration 10 μM [29]. This supports the clinical relevance of the GI50 values utilized in this study.…”

Section: Discussionsupporting

confidence: 71%

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

et al. 2011

View full text Add to dashboard Cite

BackgroundPaclitaxel is a microtubule-stabilizing drug that has been commonly used in treating cancer. Due to genetic heterogeneity within patient populations, therapeutic response rates often vary. Here we used the NCI60 panel to identify SNPs associated with paclitaxel sensitivity. Using the panel's GI50 response data available from Developmental Therapeutics Program, cell lines were categorized as either sensitive or resistant. PLINK software was used to perform a genome-wide association analysis of the cellular response to paclitaxel with the panel's SNP-genotype data on the Affymetrix 125 k SNP array. FastSNP software helped predict each SNP's potential impact on their gene product. mRNA expression differences between sensitive and resistant cell lines was examined using data from BioGPS. Using Haploview software, we investigated for haplotypes that were more strongly associated with the cellular response to paclitaxel. Ingenuity Pathway Analysis software helped us understand how our identified genes may alter the cellular response to paclitaxel.Results43 SNPs were found significantly associated (FDR < 0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607). SNPs in GRIK1, DCT, SGCD and CFTR were predicted to be intronic enhancers, altering gene expression, while SNPs in ZNF607 and BTBD12 cause conservative missense mutations. mRNA expression analysis supported these findings as GRIK1, DCT, SNTG1, SGCD and CFTR showed significantly (p < 0.05) increased expression among sensitive cell lines. Haplotypes found in GRIK1, SGCD, ROBO1, LPHN2, and PTPRD were more strongly associated with response than their individual SNPs.ConclusionsOur study has taken advantage of available genotypic data and its integration with drug response data obtained from the NCI60 panel. We identified 10 SNPs located within protein-coding genes that were not previously shown to be associated with paclitaxel response. As only five genes showed differential mRNA expression, the remainder would not have been detected solely based on expression data. The identified haplotypes highlight the role of utilizing SNP combinations within genomic loci of interest to improve the risk determination associated with drug response. These genetic variants represent promising biomarkers for predicting paclitaxel response and may play a significant role in the cellular response to paclitaxel.

show abstract

Section: Discussionsupporting

confidence: 71%

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The anticancer agent paclitaxel is an effective antirestenosis agent on drug‐eluting coronary stents, primarily due to growth inhibition of coronary artery SMC across a wide dose range 40,41 . Paclitaxel significantly inhibits cultured vascular SMC in vitro invasion and proliferation through interference with microtubule function, at concentrations 10‐ to 1,000‐fold lower than peak plasma concentrations achieved in treating human cancers and at pharmacological exposures substantially lower than those associated with minimal cytotoxicity in oncologic therapeutics 42 . In human arterial SMC cultures, the lowest paclitaxel incubating concentrations that affected proliferation (1–6 ng/mL) caused mitotic exit and G 1 phase arrest without multinucleation.…”

Section: Discussionmentioning

confidence: 99%

Drug Delivery at the Aortic Valve Tissues of Healthy Domestic Pigs with a Paclitaxel‐Eluting Valvuloplasty Balloon

Spargias

Milewski

Dębiński

et al. 2009

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…In addition, the HPLC technique is used as a standard in the pharmaceutical industry and is recognized as a standard method in American pharmacopeia. [39] In the immunoassays method, that is reported for quantification in biological samples, [40][41][42][43][44] the process consists of one reaction that binds paclitaxel to an antibody followed by incubation to form an immune complex. This complex is separated from the unbound reagent by physical or chemical separation technique and the analysis involve measuring the label activity (e.g.…”

Section: Methodsmentioning

confidence: 99%

Characteristics, Properties and Analytical Methods of Paclitaxel: A Review

Alves

Fernandes

Eloy

et al. 2018

Critical Reviews in Analytical Chemistry

View full text Add to dashboard Cite

Paclitaxel is a diterpenoid pseudoalkaloid, isolated from Taxus brevifolia, and is largely used as an antitumoral drug. The formulation of paclitaxel known as Taxol® employs a mixture of Cremophor EL and dehydrated ethanol, due the low drug water solubility. However, Taxol® causes some unwanted side effects due to the presence of Cremophor EL and ethanol in the formulation. Based on this, there is a need for the development of drug delivery systems to enhance the solubility, permeability and stability of paclitaxel and to promote a controlled and targeted delivery for better therapeutic effect and reduced side effects. In addition, the drug has been qualitatively and quantitatively analyzed in different delivery systems. In this context, several approaches were reported focusing on the optimization of analytical methods and development of new ones, considering the need of a fast, simple, with enough sensibility and selectivity assay, which can be a problem in some analysis. This review presents a summary of methods used in quantification of paclitaxel in different matrices, such as plasma, urine, plant extract, cells and delivery systems.

show abstract

Continuous-flow fluoro-immunosensor for paclitaxel measurement

Cited by 23 publications

References 27 publications

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

Drug Delivery at the Aortic Valve Tissues of Healthy Domestic Pigs with a Paclitaxel‐Eluting Valvuloplasty Balloon

Characteristics, Properties and Analytical Methods of Paclitaxel: A Review

Contact Info

Product

Resources

About